Is Mankind Pharma overvalued or undervalued?

As of 8 August 2025, Mankind Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued based on its high valuation ratios. Notable ratios include a PE ratio of 53.68, an EV to EBITDA of 33.72, and a Price to Book Value of 7.11, which are significantly higher than many peers in the industry.
In comparison, Sun Pharma has a PE ratio of 33.19 and an EV to EBITDA of 22.43, while Cipla, considered attractive, has a PE ratio of 22.23 and an EV to EBITDA of 15.61. These comparisons highlight Mankind Pharma's elevated valuation relative to its peers. Additionally, the company's stock has underperformed the Sensex year-to-date, with a return of -14.28% compared to the Sensex's 2.20%, reinforcing the notion that Mankind Pharma may be overvalued in the current market environment.